GlassScriptPhysician profile
Holly Cullen
NPI 1023048584
$3,368.56
in general payments reported to CMS, 2019-2025
36 companies · $757 in 2025
The $757 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $87.03 · 2022: $531 · 2023: $539 · 2024: $1,001 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Long Term Medical Supply Or Device Loan: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.65 |
| Long Term Medical Supply Or Device Loan | $193.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $484.46 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $463.99 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $329.47 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $280.29 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.92 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Pentax of America, INC. | $193.55 | 2024 | Video Colonoscope |
| Celgene Corporation | $165.10 | 2022-2024 | Zeposia |
| Corcept Therapeutics | $161.74 | 2024-2025 | Korlym |
| Pfizer INC. | $144.59 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.46 | 2022 | |
| Genzyme Corporation | $118.55 | 2019-2024 | |
| Lilly USA, LLC | $82.66 | 2023-2025 | Mounjaro, Omvoh |
| Ardelyx, INC. | $53.38 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $53.26 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $45.80 | 2024-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $45.47 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Biocon Biologics INC | $38.56 | 2025 | Yesintek |
| Intercept Pharmaceuticals, INC. | $30.99 | 2024-2025 | |
| Glaxosmithkline, LLC. | $29.52 | 2022-2023 | Shingrix |
| Amgen INC. | $28.62 | 2022 | |
| Ibsa Pharma INC. | $23.59 | 2025 | Tirosint, Flector, Licart |
| Medtronic, INC. | $19.30 | 2025 | Minimed 780g |
| Boston Scientific Corporation | $19.09 | 2019 | |
| Madrigal Pharmaceuticals | $19.00 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $19.00 | 2025 | Voquezna |
| Celltrion USA INC. | $18.94 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $16.94 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $15.99 | 2024 | Zinplava, Dificid |
| Fresenius Kabi USA, LLC | $15.00 | 2023 | |
| Gilead Sciences, INC. | $14.26 | 2024 | |
| Mannkind Corporation | $14.08 | 2022 | |
| 180 Medical, INC. | $13.93 | 2019 | |
| Redhill Biopharma INC. | $13.88 | 2023 | Movantik, Aemcolo, Talicia |
| Endo Pharmaceuticals INC. | $13.61 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.77 | 2019 | |
| Allergan, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Cullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.